James R Hitchin

This inventor holds 7 USPTO granted patents and 4 published patent applications, plus 1 CIPO patent and 4 EPO patents. Top assignees: Cancer Research Technology Limited, Jaguahr Therapeutics Pte Ltd. Active years: 2019-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: James R Hitchin. Retrieved from https://idiyas.com/inventor/james-r-hitchin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 (Patent Applications = 4)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 6.8

ph-index = 2

Forward Citations = 10(Granted Patents)

Company Filing History:

6 out of 268

Cancer Research Technology Limited

patents

1 out of 1

Jaguahr Therapeutics Pte Ltd

patent

Years Active: 2019-2025

Loading Chart...

7 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12221439 - Tetrahydropyridopyrimidine derivatives as AhR modulators (2025-02-11),

2. 12129236 - PARG inhibitory compounds (2024-10-29),

3. 11453666 - Autotaxin inhibitory compounds (2022-09-27),

4. 10995073 - PARG inhibitory compounds (2021-05-04),

5. 10654846 - Autotaxin inhibitory compounds (2020-05-19),

6. 10508086 - PARG inhibitory compounds (2019-12-17),

7. 10239843 - 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG (2019-03-26),

Title: James R Hitchin: Innovator in Cancer Research

Introduction

James R Hitchin is a prominent inventor based in Manchester, GB. He has made significant contributions to the field of cancer research, holding a total of 7 patents. His work focuses on developing innovative compounds that target specific enzyme activities related to proliferative disorders.

Latest Patents

Among his latest patents are the PARG inhibitory compounds, which relate to compounds that function as inhibitors of the PARG (Poly ADP-ribose glycohydrolase) enzyme activity. These compounds are crucial in the treatment of proliferative disorders, such as cancer, and other diseases where PARG activity is implicated. Another notable patent is for autotaxin inhibitory compounds, which are designed to inhibit autotaxin (ATX) enzyme activity. These compounds also have potential applications in treating proliferative disorders and conditions like fibrosis.

Career Highlights

James R Hitchin is currently associated with Cancer Research Technology Limited, where he continues to advance his research and development efforts. His innovative work has positioned him as a key figure in the fight against cancer and related diseases.

Collaborations

James has collaborated with notable colleagues, including Allan Michael Jordan and Niall M Hamilton, to further enhance the impact of his research.

Conclusion

James R Hitchin's contributions to cancer research through his innovative patents demonstrate his commitment to improving treatment options for patients. His work continues to inspire advancements in the field of medical science.

Profile summary based on public USPTO records.